Increased FDA demands affect Neurosearch-rights
Neurosearch is prepared to give up on the European rights for Huntexil in the search of a partner to finance a new phase III-study.
af KRESTEN MORTEN MUNKSGAARD
It will be more costly than previously expected for the Danish biotech company Neurosearch, if they are to succeed in securing a partner for the completion of clinical trials of the company’s Huntingtons medicine, Huntexil, according to a stock exchange release from the company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
